NATURETIN-5
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NATURETIN-5 (NATURETIN-5).
Thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, decreasing sodium and water reabsorption and reducing intravascular volume and blood pressure.
| Metabolism | Not extensively metabolized; undergoes minor hepatic metabolism via CYP450 isoenzymes. |
| Excretion | Primarily renal (70-80% as unchanged drug); the remainder (20-30%) is eliminated via biliary/fecal routes. |
| Half-life | Terminal elimination half-life is approximately 18-24 hours; clinically, this supports once-daily dosing and requires renal function monitoring. |
| Protein binding | Saturable binding to erythrocytes; approximately 95% protein-bound, primarily to albumin. |
| Volume of Distribution | 0.8-1.4 L/kg; indicates extensive extravascular distribution and tissue binding. |
| Bioavailability | Oral: 60-70%; hepatic first-pass metabolism accounts for reduced bioavailability. |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-15 minutes. |
| Duration of Action | 12-24 hours; diuretic and antihypertensive effects may persist for up to 24 hours, allowing for once-daily dosing. |
| Molecular Weight | 445.5 Da |
5 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: 2.5 mg once daily; GFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B/C: contraindicated. |
| Pediatric use | Not recommended; safety and efficacy not established. |
| Geriatric use | Initiate at 2.5 mg orally once daily; titrate cautiously. |
| 1st trimester | Avoid due to risk of fetal abnormalities; may cause hypovolemia and reduced placental perfusion. |
| 2nd trimester | Use only if clearly needed; monitor fetal growth and amniotic fluid volume. |
| 3rd trimester | Contraindicated; may cause fetal hypotension, oligohydramnios, and neonatal adaption difficulties. |
Clinical note
Comprehensive clinical and safety monograph for NATURETIN-5 (NATURETIN-5).
| Placental transfer | Crosses placenta; evidence of transfer in animal models and human data (limited). |
| Breastfeeding | Excreted in breast milk in low amounts; potential for adverse effects in nursing infants (e.g., electrolyte disturbances). Use with caution, especially in preterm or jaundiced infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
AnuriaSevere renal impairment (CrCl <30 mL/min)Hepatic coma or pre-comaSevere electrolyte disturbances (e.g., hyponatremia, hypokalemia)Hypersensitivity to bendroflumethiazide or sulfonamidesPregnancy (especially third trimester)
| Precautions | Hypokalemia, Hypomagnesemia, Hyponatremia, Hyperuricemia and gout, Hypercalcemia, Dehydration and orthostatic hypotension, Exacerbation of systemic lupus erythematosus, Metabolic alkalosis, Sulfonamide cross-sensitivity |
| Food/Dietary | Avoid excessive intake of foods high in potassium (e.g., bananas, oranges, tomatoes) unless directed by a doctor. Limit alcohol consumption as it may increase orthostatic hypotension. Maintain adequate fluid intake unless fluid restriction is advised. |
Loading safety data…
| L3 (Moderately Safe) - use only if benefit outweighs risk. |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: risk of congenital malformations, including neural tube defects, cardiovascular anomalies. Second and third trimesters: increased risk of fetal/neonatal adverse effects like oligohydramnios, renal dysfunction, and skull ossification defects. |
| Fetal Monitoring | Monitor maternal blood pressure, electrolytes, and renal function. Perform fetal ultrasound for growth and amniotic fluid index. Monitor for signs of oligohydramnios and fetal distress. |
| Fertility Effects | May affect fertility by causing reversible gynecomastia and sexual dysfunction in males. Females may experience menstrual irregularities. Impact on ovulation or spermatogenesis not fully elucidated. |
| Clinical Pearls | NATURETIN-5 contains bendroflumethiazide 5 mg, a thiazide diuretic. Monitor serum potassium, sodium, and magnesium; hypokalemia may potentiate digoxin toxicity. Use with caution in patients with gout or hyperuricemia. Onset of action is 2 hours, peak effect at 4 hours, duration 12-24 hours. |
| Patient Advice | Take this medication in the morning to avoid nighttime urination. · Avoid excessive sunlight or use sunscreen as this drug may increase photosensitivity. · Do not stop taking this medication abruptly without consulting your doctor. · Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst. |